410 related articles for article (PubMed ID: 26216863)
1. Heart rate variability in major depressive disorder and after antidepressant treatment with agomelatine and paroxetine: Findings from the Taiwan Study of Depression and Anxiety (TAISDA).
Yeh TC; Kao LC; Tzeng NS; Kuo TB; Huang SY; Chang CC; Chang HA
Prog Neuropsychopharmacol Biol Psychiatry; 2016 Jan; 64():60-7. PubMed ID: 26216863
[TBL] [Abstract][Full Text] [Related]
2. Effects of depression and melatonergic antidepressant treatment alone and in combination with sedative-hypnotics on heart rate variability: Implications for cardiovascular risk.
Chang CC; Tzeng NS; Yeh CB; Kuo TBJ; Huang SY; Chang HA
World J Biol Psychiatry; 2018 Aug; 19(5):368-378. PubMed ID: 28281386
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Agomelatine vs Paroxetine Hydrochloride in Chinese Han Patients with Major Depressive Disorder: A Multicentre, Double-Blind, Noninferiority, Randomized Controlled Trial.
Yu YM; Gao KR; Yu H; Shen YF; Li HF
J Clin Psychopharmacol; 2018 Jun; 38(3):226-233. PubMed ID: 29620692
[TBL] [Abstract][Full Text] [Related]
4. Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on measures of nonlinearity and chaos of heart rate.
Yeragani VK; Roose S; Mallavarapu M; Radhakrishna RK; Pesce V
Neuropsychobiology; 2002; 46(3):125-35. PubMed ID: 12422059
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline.
Kasper S; Hajak G; Wulff K; Hoogendijk WJ; Montejo AL; Smeraldi E; Rybakowski JK; Quera-Salva MA; Wirz-Justice AM; Picarel-Blanchot F; Baylé FJ
J Clin Psychiatry; 2010 Feb; 71(2):109-20. PubMed ID: 20193645
[TBL] [Abstract][Full Text] [Related]
6. Changes in heart rate variability in first-episode drug-naïve adolescents with major depressive disorder: A 12-week prospective study.
Park SW; Lee JH; Kim J; Suh S; Lee MS
J Affect Disord; 2018 Oct; 238():250-255. PubMed ID: 29890452
[TBL] [Abstract][Full Text] [Related]
7. Once-daily duloxetine 60 mg in the treatment of major depressive disorder: multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil.
Lee P; Shu L; Xu X; Wang CY; Lee MS; Liu CY; Hong JP; Ruschel S; Raskin J; Colman SA; Harrison GA
Psychiatry Clin Neurosci; 2007 Jun; 61(3):295-307. PubMed ID: 17472599
[TBL] [Abstract][Full Text] [Related]
8. Comparable efficacy and safety of 8 weeks treatment with agomelatine 25-50mg or fluoxetine 20-40mg in Asian out-patients with major depressive disorder.
Shu L; Sulaiman AH; Huang YS; Fones Soon Leng C; Crutel VS; Kim YS
Asian J Psychiatr; 2014 Apr; 8():26-32. PubMed ID: 24655622
[TBL] [Abstract][Full Text] [Related]
9. Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on long-term heart rate variability measures.
Yeragani VK; Pesce V; Jayaraman A; Roose S
Biol Psychiatry; 2002 Sep; 52(5):418-29. PubMed ID: 12242058
[TBL] [Abstract][Full Text] [Related]
10. Reactive heart rate variability in male patients with first-episode major depressive disorder.
Liang CS; Lee JF; Chen CC; Chang YC
Prog Neuropsychopharmacol Biol Psychiatry; 2015 Jan; 56():52-7. PubMed ID: 25149628
[TBL] [Abstract][Full Text] [Related]
11. Low cardiac vagal tone index by heart rate variability differentiates bipolar from major depression.
Hage B; Britton B; Daniels D; Heilman K; Porges SW; Halaris A
World J Biol Psychiatry; 2019 Jun; 20(5):359-367. PubMed ID: 28895492
[No Abstract] [Full Text] [Related]
12. Treating each and every depressed patient.
Kennedy SH
J Psychopharmacol; 2008 Sep; 22(7 Suppl):19-23. PubMed ID: 18753279
[TBL] [Abstract][Full Text] [Related]
13. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study.
Lôo H; Hale A; D'haenen H
Int Clin Psychopharmacol; 2002 Sep; 17(5):239-47. PubMed ID: 12177586
[TBL] [Abstract][Full Text] [Related]
14. Hypomania soon after shifting from paroxetine to agomelatine in a middle-aged woman with depression.
Tu KY; Lin PY
Clin Neuropharmacol; 2014; 37(3):82-3. PubMed ID: 24824663
[TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy of agomelatine in depression: the evidence.
den Boer JA; Bosker FJ; Meesters Y
Int Clin Psychopharmacol; 2006 Feb; 21 Suppl 1():S21-4. PubMed ID: 16436936
[TBL] [Abstract][Full Text] [Related]
16. Distinguishing bipolar II depression from unipolar major depressive disorder: Differences in heart rate variability.
Chang HA; Chang CC; Kuo TB; Huang SY
World J Biol Psychiatry; 2015; 16(5):351-60. PubMed ID: 25800950
[TBL] [Abstract][Full Text] [Related]
17. Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial.
Stahl SM; Fava M; Trivedi MH; Caputo A; Shah A; Post A
J Clin Psychiatry; 2010 May; 71(5):616-26. PubMed ID: 20361916
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder.
Olié JP; Kasper S
Int J Neuropsychopharmacol; 2007 Oct; 10(5):661-73. PubMed ID: 17477888
[TBL] [Abstract][Full Text] [Related]
19. Heart rate variability as a biomarker of anxious depression response to antidepressant medication.
Kircanski K; Williams LM; Gotlib IH
Depress Anxiety; 2019 Jan; 36(1):63-71. PubMed ID: 30311742
[TBL] [Abstract][Full Text] [Related]
20. Agomelatine: efficacy at each phase of antidepressant treatment.
Kennedy SH
CNS Drugs; 2009; 23 Suppl 2():41-7. PubMed ID: 19708725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
